OncoSec Medical
we are a biotech company focused on creating treatments for advanced-stage skin cancer. We focus on three cure-resistant and all-too-often fatal skin cancers: melanoma, Merkel cell lymphoma, and cutaneous T-cell lymphoma.
One in five Americans will be diagnosed with skin cancer in their lifetime. Each one will face the reality of an insufficiently developed treatment landscape, limited options, and uncertain outcomes.

This year alone, more than 10,000 will die.

A cure needs to be found, and it needs to happen sooner. At OncoSec, we are accelerating the search for a cure so that people diagnosed today can have hope for the future.

OncoSec’s proprietary technology is based on electroporation, a process that opens temporary pores in the cell membrane of infected cells through which an anti-cancer agent can be transmitted more effectively.
Using brief electrical pulses, we can target tumor cells with greater accuracy and power. Electroporation not only increases the delivery of proven drug therapies, it narrows the target to reduce or eliminate spillover toxic effects. This proprietary technology allows us to “correct the dots”—treating only the cancerous cells and leaving healthy tissue intact.

Pre-clinical and clinical data to date show that the approach is both safe and highly effective. Now we’re ready to take a step closer to our ultimate goal of replacing uncertainty with hope for cancer sufferers everywhere.

In the coming months and years, watch us correct the dots. Millions of them, around the world.